Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 8
Submit an article Journal homepage
416
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Tolerability and efficacy of rituximab-containing immunochemotherapy in patients with B-cell non-Hodgkin lymphoma receiving hemodialysis

Yotaro OchiDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan;
,
Nobuhiro HiramotoDepartment of Cell Therapy, Institute of Biomedical Research and Innovation, Kobe, Japan; Correspondence[email protected]
,
Yuichiro OnoDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan;
,
Satoshi YoshiokaDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan;
,
Sumie TabataDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan;
,
Noboru YonetaniDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan;
,
Akiko MatsushitaDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan;
,
Yukihiro ImaiDepartment of Clinical Pathology, Kobe City Medical Center General Hospital, Kobe, Japan
&
Takayuki IshikawaDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan;
show all
Pages 1945-1948 | Received 02 Sep 2015, Accepted 24 Oct 2015, Published online: 21 Dec 2015

References

  • White SL, Chadban SJ, Jan S, et al. How can we achieve global equity in provision of renal replacement therapy? Bull World Health Organ. 2008;86:229–237.
  • Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet. 1999;354:93–99.
  • Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296:2823–2831.
  • Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242.
  • de Barros Pontes L, Todaro J, Karnakis T, et al. Treatment of a frail older patient with diffuse large B-cell lymphoma on maintenance dialysis: attenuated immunochemotherapy and adapted care plan. Case Rep Oncol. 2013;6:197–203.
  • Feldmann G, Nattermann J, Gerhardt T, et al. Partial remission of a newly diagnosed diffuse large B-cell Non-Hodgkin's lymphoma in a hemodialysis patient after administration of immuno-chemotherapy with rituximab-CHOP. Int J Lab Hematol. 2007;29:469–473.
  • Kawano N, Yokota-Ikeda N, Kawano S, et al. Successful treatment of non-Hodgkin's lymphoma with rituximab and dose-adjusted CHOP therapy in a patient with concomitant end-stage renal disease requiring haemodialysis. NDT Plus. 2011;4:186–189.
  • Aoki K, Takahashi T, Tabata S, et al. Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2013;54:2441–2447.
  • Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.
  • Terada Y, Nakamae H, Aimoto R, et al. Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma. J Exp Clin Cancer Res. 2009;28:116.
  • Jillella AP, Dainer PM, Kallab AM, Ustun C. Treatment of a patient with end-stage renal disease with Rituximab: pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis. Am J Hematol. 2002;71:219–222.
  • Janus N, Thariat J, Boulanger H, et al. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol. 2010;21:1395–1403.
  • Watanabe T, Tobinai K, Shibata T, et al. Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial. J Clin Oncol. 2011;29:3990–3998.
  • Girndt M, Sester U, Sester M, et al. Impaired cellular immune function in patients with end-stage renal failure. Nephrol Dial Transplant. 1999;14:2807–2810.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.